Review

Does route of administration affect the outcome of TNF antagonist therapy?

Sergio Schwartzman1 and G James Morgan Jr2

1Hospital for Special Surgery, New York, NY, USA
2Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA

Corresponding author: Sergio Schwartzman (e-mail: schwartzmans@hss.edu)

Received: 17 Jul 2003  Accepted: 6 Aug 2003  Published: 21 Jun 2004

Arthritis Res Ther 2004, 6(Suppl 2):S19-S23 (DOI 10.1186/ar996)
© 2004 BioMed Central Ltd (Print ISSN 1478-6354; Online ISSN 1478-6362)

Abstract

The tumor necrosis factor (TNF) antagonists are parenterally administered biologic response modifiers indicated for the management of rheumatoid arthritis. Although infliximab, etanercept, and adalimumab are all members of this class, they differ in route of administration and dosing regimen. In the USA and in Europe, infliximab, in combination with oral methotrexate, is administered intravenously, initially at a dose of 3 mg/kg at weeks 0, 2, and 6, then every 8 weeks thereafter. The US Food and Drug Administration (FDA) has further approved that the dosage can be increased to 10 mg/kg and the doses can be given as often as every 4 weeks to optimize patient outcome (information based on the US package insert dated June 2002). Etanercept and adalimumab are given subcutaneously and can be self-injected. The FDA-approved dose of etanercept is 25 mg twice weekly, and of adalimumab is 40 mg every 2 weeks with methotrexate, or 40 mg alone. Medication adherence, possibly the most important factor in maintaining the benefits of anti-TNF therapy, is influenced by the interaction between the patient and his or her healthcare team, the patient’s attitude toward the disease and medication regimen, and the choice of therapy.

Keywords: adherence, efficacy, intravenous, rheumatoid arthritis, subcutaneous, tumor necrosis factor

Introduction

The introduction of tumor necrosis factor (TNF) antagonists has been a major advance in the treatment of patients with rheumatoid arthritis (RA). These agents have been shown to significantly decrease pain, joint swelling, serologic inflammatory indices, and rates of radiologic damage [1–6]. In addition, anti-TNF therapy has led to significant improvements in physical function and overall quality of life, as shown by improvements in Health Assessment Questionnaire (HAQ) scores and as determined by the Medical Outcomes Study Short-Form Health Survey (SF-36) [1,5].

All of the TNF antagonists are administered parenterally [7–9]. Infliximab (Remicade®; Centocor, Inc., Malvern, PA, USA) is administered intravenously (IV) at an initial dose of 3 mg/kg at weeks 0 (baseline), 2, and 6, then every 8 weeks thereafter. In select patients, the dose can be increased to 10 mg/kg and/or the interval between infusions can be shortened to 4 weeks to optimize response to therapy [8]. Infliximab is given in combination with oral methotrexate, usually in an office-based setting [8]. Etanercept (Enbrel®; Immunex Corp, Seattle, WA, USA) is administered subcutaneously (SC) at a dosage of 25 mg twice weekly [7], and adalimumab (Humira™; Abbott Laboratories, Abbott Park, IL, USA) is planned for SC administration at a dosage of 40 mg every 2 weeks with methotrexate [9]. Etanercept and adalimumab are primarily self-administered at home, provided that the patient has no functional limitations.

The difference in routes of administration and dosing regimens between infliximab, etanercept, and adalimumab raises the question of whether these differences affect
adherence to therapy and therapeutic outcomes. To explore this question we examine the experiences of patients with chronic disorders other than RA.

**Relationship between route of administration and disease outcome**

Studies have indicated that the TNF inhibitors seem to have equivalent short-term efficacies despite the different routes of administration. However, it is believed that long-term effectiveness is probably influenced by adherence to the drug regimen, and poor adherence to long-term therapies can severely compromise the effectiveness of treatment [10]. Efficacy (the extent to which a specific intervention produces a beneficial effect under ideal conditions) is based mainly on the pharmacologic effects of a particular therapy, whereas effectiveness (the extent to which a specific intervention produces a beneficial effect when used in the community) takes into account many other aspects, including patient characteristics, health system attributes, and societal factors [11,12].

Treatment adherence in patients with RA has not been well studied, but a review of adherence rates to treatment regimens for other chronic diseases might provide a logical point of comparison. Among adults and children who have hypertension, asthma, HIV infection, and depression, adherence rates to treatments average 50% worldwide (Table 1) [10].

Adherence, or the lack of it, depends on four factors: (1) the healthcare team, (2) the disease, (3) the patient, and (4) the therapy [10].

**Factors influencing adherence**

Polypharmacy (the prescription of many drugs or ingredients) has been shown to reduce adherence, especially in the elderly [13]. Patients who take several drugs or drugs with multiple dosing or complex regimens are less likely to take their medications than are patients who take fewer drugs or drugs with simpler regimens. Provider inconsistency, in which the patient sees a different physician at each visit, can also limit adherence. Accessibility to physicians and their healthcare staff will enhance adherence to treatment, as will adequate patient education.

Very limited data are available about the effect of pain and disability on adherence to therapy in patients with RA [14]. Studies of other chronic diseases such as asthma suggest that symptom severity might not correlate well with adherence to therapy [15]. Pain, stiffness, and physical deformities could be relevant if they significantly affect the ability of the patient to self-inject required medications.

Three patterns of treatment non-adherence have been observed in patients: (1) erratic non-adherence, often due to forgetfulness; (2) unwitting non-adherence, due to a limited understanding of the treatment regimen; and (3) intelligent non-adherence, in which the patient’s health beliefs prompt a conscious decision not to adhere to the treatment. Asthma studies in which medication dosing is monitored electronically reveal large discrepancies between self-reported and recorded medication use. Similar discrepancies exist between patient and physician reports of medication use [16,17]. In one pediatric asthma study investigating the self-administration of β-agonists, inhaled steroids, and cromolyn, respective discordance rates of 20%, 67%, and 50% were observed between parents’ reports of their children’s medication use and the physicians’ actual prescriptions [17].

Poor understanding of the purpose of a medication can also lead to limited adherence. A Canadian survey of 603 patients with asthma was conducted to determine patient perceptions of the role of inhaled corticosteroids in asthma [16]. Results showed that a considerable number of asthma patients did not understand how corticosteroids work. Between 41% and 43% of patients believed that corticosteroids acted to open the airways and relieve constriction (which is not true; bronchodilators do this), whereas only 22% to 24% of patients in this study believed that corticosteroids reduce inflammation or swelling of the airways (which they do) [16].

Four factors in patients that have been associated with poor adherence are denial, disruption, depression, and dementia. In cases of denial, the patient often believes that he or she is not sufficiently ill to warrant the prescribed therapy, which leads to diminished adherence. Disruption describes any factor, such as a personal or family crisis, that interrupts the patient’s daily schedule and therefore his or her medication regimen. Depression often manifests itself as apathy and not caring about getting well, and dementia frequently precludes a patient’s ability to follow a prescribed regimen.

### Table 1

| Disease   | Country | Adherence rate (%) |
|-----------|---------|--------------------|
| Hypertension | USA  | 51                |
|           | Gambia | 27                |
| Asthma     | Australia | 27-43           |
| HIV/AIDS   | Worldwide | 37-83           |
| Depression | USA   | 40-70             |
| Overall    |        | ~50               |

Data from the World Health Organization [10].
The adverse event profile of a therapy, the cost of therapy and, potentially, the route of administration influence patient adherence. In addition, failure to respond to a therapy can limit patient adherence. Unfortunately, the long-term efficacy and effectiveness of a drug can be underestimated because of poor patient adherence [12]. Future research will need to focus on RA-specific factors that affect long-term adherence and the use of monitoring methods (such as direct observation, electronic monitoring, random home visits, syringe counts, or self-reporting) to assess patient adherence to injectable drugs.

**Subcutaneous versus intravenous dosing**

Specific aspects relating to the route of administration include the onset of efficacy, immunogenicity, and patient preference. Commonly cited advantages of SC and IV dosing are listed in Table 2.

**SC dosing**

Because many SC injections are self-administered, an advantage of SC dosing is patient control over when and where the patient will receive his or her medication, and a lack of associated (namely office-related) costs. In fact, physicians may prefer SC dosing for patients who would otherwise have to travel a long distance to receive an IV infusion.

A disadvantage of SC dosing is limited flexibility; patients must adhere to specific incremental dosage increases. There is no flexibility in the dosing of etanercept [7]. It is not known whether there will be flexibility in the dosing of adalimumab. In addition, there can be functional limitations to SC dosing, because not all patients are physically able to inject themselves, possibly as a result of progressive RA. Attempts to overcome these limitations include the development of syringes with bigger wings and larger caps, and preloaded syringes that do not require reconstitutions of the medication (Fig. 1). These modifications are expected to be introduced with adalimumab (data on file, Abbott Laboratories).

The scientific literature suggests that the likelihood of an immune response to a biologic agent is greater after SC administration than after an IV infusion [18]. However, the rate of anti-product antibody formation, allergic reactions, efficacy, and the incidence of autoimmune syndromes (for example, systemic lupus erythematosus) after SC administration remain to be determined.

**IV dosing**

IV dosing allows continuous dosage adjustments to be made, affording flexibility in matching patient needs at any given time during the infusion and helping to optimize overall treatment outcomes. One of the early RA trials with adalimumab evaluated IV and SC dosing, with double-blind and open-label phases (Fig. 2) (data on file, Abbott Laboratories). In the blinded phase, 54 patients were randomized to receive the study drug IV or placebo SC, the study drug IV or placebo IV, or the study drug SC or placebo IV, with a 3-week washout period for non-methotrexate disease-modifying antirheumatic drugs; the second injection was given at the same dose by the same route after initial response had faded (no sooner than 4 weeks after the first injection) (data on file, Abbott Laboratories).

In the open-label phase, patients were given the study drug SC and were followed for less than 18 months (data on file, Abbott Laboratories). Overall, the IV and SC dosing with adalimumab showed similar results in efficacy endpoints (namely American College of Rheumatology [ACR]20, ACR50, and European League Against Rheumatism [EULAR] responses) (data on file, Abbott Laboratories).
In terms of tender and swollen joint counts, the IV group showed a more rapid response than the SC group, whereas the placebo group showed no adequate response (data on file, Abbott Laboratories).

In terms of reimbursement issues related to the use of anti-TNF agents in RA, IV dosing might hold an advantage over SC dosing, especially in patients with Medicare coverage. Generally, coverage for drugs and biologic agents is provided by Medicare only if such agents (1) meet the definition of drugs/biologics, (2) are of the type that cannot be self-administered, (3) meet all general requirements for coverage of items as incident to a physician's services, (4) are not excluded as immunizations, and (5) have not been determined by the US Food and Drug Administration to be less than effective [19].

When selecting a TNF antagonist, the patient’s preference for route of administration is a significant factor. Jarry and colleagues [20] conducted a literature review based on MEDLINE searches to assess the expected compliance profiles of infliximab and etanercept in patients with RA. Data about compliance for all parenterally administered medications in patients with RA and other illnesses were reviewed. In general, compliance was noted to be poor in patients with RA regardless of route of administration. In patients with illnesses other than RA, treatment by means of assisted IV infusions had higher compliance rates than self-administered SC injections. A survey that asked which route of administration for anti-TNF therapy was preferred by Canadian patients with RA was also conducted. Results indicated a preference for IV administration (that is, with infliximab) over an SC regimen (that is, with etanercept). In this survey, factors for this preference included patients’ general dislike of SC injections, pain and irritation at the injection site, more frequent administration of the SC-administered drug (etanercept), difficulty in handling secure medication containers, and the clinical assistance attendant on IV administration (Fig. 3) [21].

In a study by Tice, more than 95% of outpatients receiving antibiotics for an infectious disease reported a preference for IV administration [22]. In addition, it was reported that 70% of cancer chemotherapy is administered IV in an outpatient setting.

The most common setting for the administration of infliximab is in community-based or academically based clinics. Other settings include the outpatient section of a hospital,
independent free-standing infusion units, and the patient’s home, although most infliximab infusions are administered outside the home. Some hospitals are introducing immuno-
mediated inflammatory disease (IMID) centers, where various
types of disease (for example rheumatic, metabolic, gastroin-
testinal, ophthalmic, neoplastic, hematologic, and infectious) are managed with IV medications in a single setting.

Healthcare workers who administer IV medications should be familiar with the toxicities that can occur after infusing any IV agent and should be able to manage these reac-
tions. Other methods of ensuring safety include the adhere-
tance to standardized protocols for the infusion procedure;
patient assessments before, during, and after the proce-
dure; and careful follow-up. Ancillary benefits of IV therapy include continuity of care, better patient education, peer
support, and access to other medical specialists and
support staff (such as social workers, nutritionists, and occupational/physical therapists).

Conclusion
In clinical trials the TNF antagonists infliximab, etanercept,
and adalimumab seem to have equivalent short-term effica-
cies despite the different routes of administration of these
agents. However, the long-term efficacy of the TNF antago-
nists in patients with RA is significantly influenced by the
degree of adherence to the therapeutic regimen. Factors
influencing adherence include the healthcare team (for example, interaction with the patient, patient education), the
disease itself (for example, symptom severity), the patient
(for example, attitude toward therapy), and the therapy
chosen (for example, potential adverse events, cost, route of
administration). Does the route of administration influence the outcomes of anti-TNF therapy? There are indications that it might, although this question needs to be evaluated
qualitatively and quantitatively by further research.

Competing interests
SS is a speaker for Centocor, Abbott and Boehringer. GJM is a consultant for Centocor, and on the Speaker’s Bureau for Abbott and Centocor.

Acknowledgement
The transcript of the World Class Debate for ACR 2002 has been pub-
lished electronically in Joint and Bone. This article, and others pub-
lished in this supplement, serve as a summary of the proceedings as
well as a summary of other supportive, poignant research findings (not included in the World Class Debate ACR 2002).

References
1. Lipsky PE, van der Heijde DMFM, St Clair EW, Furat DE, Breed-
veld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann
M, Harriman GR, Maini RN, for the Anti-Tumor Necrosis Factor
Trial in Rheumatoid Arthritis With Concomitant Therapy Study
Group: Infliximab and methotrexate in the treatment of
rheumatoid arthritis. N Engl J Med 2000, 343:1594-1602.
2. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M,
Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P, for the
ATTRACT Study Group: Infliximab (chimeric anti-tumour necro-
sis factor α monoclonal antibody) versus placebo in rheuma-
toid arthritis patients receiving concomitant methotrexate: a
randomised phase III trial. Lancet 1999, 354:1932-1939.
3. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfar-
lane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schable TF,
Feldmann M: Therapeutic efficacy of multiple intravenous infu-
sions of anti-tumor necrosis factor α monoclonal antibody
combined with low-dose weekly methotrexate in rheumatoid
arthritis. Arthritis Rheum 1998, 41:1552-1563.
4. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH,
Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver
AL, Markenson J, Finck BK: A comparison of etanercept and
methotrexate in patients with early rheumatoid arthritis. N
Engl J Med 2000, 343:1586-1593.
5. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser
JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver
AL, Markenson J, Cannon GW, Spencer-Green G, Finck BK:
Etanercept versus methotrexate in patients with early
rheumatoid arthritis: two-year radiographic and clinical out-
comes. Arthritis Rheum 2002, 46:1443-1450.
6. Morgan GJ Jr, Chow WS: Clinical features, diagnosis, and
prognosis in rheumatoid arthritis. Curr Opin Rheumatol 1993,
5:184-190.
7. Medical Economics Company Inc: Prescribing information:
Enbrel®. In Physicians’ Desk Reference®, Montvale, NJ;
2002:3504-3507.
8. Centocor, Inc.: Remicade®: Package insert, revised June 2002.
Malvern, PA; 2002.
9. Abbott Laboratories: Humira®: Package insert. Abbott Park, IL;
2002.
10. World Health Organization: World Health Organization: Noncom-
municable Diseases and Mental Health – Adherence to Long-
term Therapies: Policy for Action. Meeting Report 4–5 June,
2001, Geneva: WHO/MNC/CH/01.02; 2001.
11. Fleischmann R: In quest of the Holy Grail: efficacy versus
effectiveness in rheumatoid arthritis [letter]. J Rheumatol
2002, 29:2018-2019.
12. Suarez-Almazor ME: In quest of the holy grail: efficacy versus
effectiveness in rheumatoid arthritis [editorial]. J Rheumatol
2002, 29:209-211.
13. Williams CM: Using medications appropriately in older adults.
Am Fam Physician 2002, 66:1917-1924.
14. Viller F, Guillemin F, Briancon S, Moun M, Suurmeijer T, van den
HW: Compliance to drug treatment of patients with rheuma-
toid arthritis: a 3 year longitudinal study. J Rheumatol 1999,
26:2114-2122.
15. Kuehni CE, Frey U: Age-related differences in perceived
asthma control in childhood: guidelines and reality. Eur Respir
J 2002, 20:880-889.
16. Boulet LP: Perception of the role and potential side effects of
inhaled corticosteroids among asthmatic patients. Chest
1998, 113:587-592.
17. Winkelstein ML, Huss K, Butz A, Eggleston P, Vargas P, Rand C:
Factors associated with medication self-administration in
children with asthma. Clin Pediatr (Phila) 2000, 39:337-345.
18. Porter S: Human immune response to recombinant human
proteins. J Pharm Sci 2001, 90:1-11.
19. Centers for Medicare and Medicaid Services: Drugs and biologi-
cals. In: Carriers Manual (Publication 14-3), Chapter II, Section
2049, Baltimore, MD; 2002.
20. Jarry JL, Coambs RB, De Maio FG, Rattray AH, Balaram R,
Russell A: Projected patterns of compliance associated with
Remicade (infliximab) and Enbrel (etanercept) [abstract]. J
Rheumatol 2002, 29:1564.
21. Jarry JL, Coambs RB, De Maio FG, Rathay AH, Balaram R:
Expected compliance profiles of the new anti rheumatic,
infliximab and etanercept [poster]. [http://www.healthpromore-
search.com/ILAR%20poster%20for%20print.pdf]
22. Tice AD: Alternate site infusion: the physician-directed, office-
based model. J Intraven Nurs 1996, 19:188-193.

Correspondence
Sergio Schwartzman MD, Hospital for Special Surgery, 355 East 70th
Street, New York, NY 10021, USA. Tel: +1 212 606 1557; fax: +1
212 794 2527; e-mail: schwartzmans@hss.edu

Available online http://arthritis-research.com/content/6/S2/S19